Literature DB >> 7389234

Antipyrine half-life and drug elimination.

A Breckenridge.   

Abstract

Mesh:

Substances:

Year:  1980        PMID: 7389234     DOI: 10.2165/00003088-198005030-00001

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


× No keyword cloud information.
  4 in total

1.  A re-evaluation of intersubject variation in enzyme induction in man.

Authors:  R A Branch; D G Shand
Journal:  Clin Pharmacokinet       Date:  1979 Mar-Apr       Impact factor: 6.447

2.  Further observations on relationships between antipyrine half-life, clearance and volume of distribution: an appraisal of alternative kinetic parameters used to assess the elimination of antipyrine.

Authors:  L G Sultatos; B H Dvorchik; E S Vesell; D G Shand; R A Branch
Journal:  Clin Pharmacokinet       Date:  1980 May-Jun       Impact factor: 6.447

3.  Genetic control of the phenobarbital-induced shortening of plasma antipyrine half-lives in man.

Authors:  E S Vesell; J G Page
Journal:  J Clin Invest       Date:  1969-12       Impact factor: 14.808

4.  The relationship between liver volume, antipyrine clearance and indocyanine green clearance before and after phenobarbitone administration in man.

Authors:  C J Roberts; L Jackson; M Halliwell; R A Branch
Journal:  Br J Clin Pharmacol       Date:  1976-10       Impact factor: 4.335

  4 in total
  3 in total

Review 1.  Progress in clinical pharmacology over the last 20 years.

Authors:  Michel Eichelbaum
Journal:  Br J Clin Pharmacol       Date:  2003-05       Impact factor: 4.335

2.  Enhanced drug metabolism after sulfinpyrazone treatment in patients aged 50 to 60 years.

Authors:  E Walter; C Staiger; J de Vries; E Weber; W Bitzer; M Degott; K Jüngling
Journal:  Klin Wochenschr       Date:  1982-11-15

3.  Salivary antipyrine half-life during injectable progestagen contraception.

Authors:  J V Joshi; K C Gupta; K T Hazari; J Gokral; S Pohujani; R Satoskar
Journal:  Clin Pharmacokinet       Date:  1986 Mar-Apr       Impact factor: 6.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.